Dengue Vaccine Could Be Available In Four Years

A vaccine against the mosquito-borne infection dengue, the first to reach the final stage of clinical testing, “has seen ‘very promising’ results in Thailand, a specialist involved in the tests said on Friday,” Reuters reports (Petty/Mahlich, 6/10). The vaccine, which is being developed by the French pharmaceutical group Sanofi, could be launched in four years, according to Agence France-Presse. Dengue, for which there is no treatment or cure, causes severe flu-like symptoms and infects about 50 million people worldwide annually, killing thousands, primarily in developing countries (6/10).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.